Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma

Journal of the National Cancer Institute

Volumn 93, Issue 7, 2001, Pages 516-525

  Guruswamy, Suresh ^a   Lightfoot, Stan ^a   Gold, Michael A ^a   Hassan, Raffit ^a   Berlin, K Darrell ^b   Ivey, R Todd ^a   Benbrook, Doris M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4,4 DIMETHYL 3,4 DIHYDRO 2H BENZO[B]PYRAN 6 YL)CARBONYLOXY]BENZALDEHYDETHIOSEMICARBAZONE; ALITRETINOIN; ETHYL 4 (4,4 DIMETHYL N ISOPROPYL 1,2,3,4 TETRAHYDROQUINOLIN 6 OYLOXY)BENZOATE; ETHYL 4 (N,4,4,7 TETRAMETHYL 1,2,3,4 TETRAHYDROQUINOLIN 6 OYLOXY)BENZOATE; ETHYL 4 [(3 METHOXY 5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYLNAPHTHALEN 2 YL)CARBONYLOXY]BENZOATE; FENRETINIDE; KI 67 ANTIGEN; METHYL 4 (4,4,5,7 TETRAMETHYL 6 COUMARYL)BENZOATE; METHYL 4 [(2,3 DIHYDRO 2,2,4,4 TETRAMETHYL 2H 1 BENZOTHIOPYRAN 6 YL)CARBAMOYL]BENZOATE; MUCIN; N 4 [(2,3 DIHYDRO 2,2,4,4 TETRAMETHYL 2H 1 BENZOTHIOPYRAN 6 YL) N' 4 NITROPHENYL]THIOUREA; RETINOID DERIVATIVE; UNCLASSIFIED DRUG; [(2,3 DIHYDRO 2,2,4,4 TETRAMETHYL 2H 1 BENZOTHIOPYRAN 6 YL) N' 4 ETHOXYCARBONYLPHENYL]THIOUREA; [N 4 (2,3 DIHYDRO 2,2,4,4 TETRAMETHYL 2H 1 BENZOTHIOPYRAN 6 YL) N' 4 ETHOXYCARBONYLPHENYL]UREA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; NICK END LABELING; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

EID: 0035804648     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.7.516     Document Type: Article

References (53)

1. Cancer statistics, 2000
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
3. Hereditary ovarian cancer: Molecular genetics and clinical implications
4. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2
5. Chemoprevention of breast cancer with retinoids
6. Can fenretinide protect women against ovarian cancer?
7. Prevention of cancer in the next millennium
8. Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling
9. Regulation of gene expression by vitamin A: The role of nuclear retinoic acid receptors
10. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid
11. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1 binding site in the CYP4A6 promoter
12. The steroid receptor superfamily: More excitement predicted for the future
13. Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling
14. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor sub-family
15. Identification of a retinoic acid responsive element in the retinoic acid receptor β gene
16. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors
17. N-4-Hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism
18. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells
19. The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells
20. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines
21. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide
22. Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells
23. Fenretinide: Induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells
24. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines
25. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
26. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-napthalene carboxylic acid (CD437)
27. All-trans-retinoic acid enhances cisplatin-induced apoptosis in human ovarian and in squamous head and neck cancer cells
28. Clinical pharmacology of the retinoids
29. Chemoprevention of breast cancer with fenretinide (4-HPR): Study of long-term visual and ophthalmologic tolerability
30. Biologically active heteroarotinoids exhibiting anti-cancer activity and decreased toxicity
31. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors
32. Synthesis, structure-activity relationships, and RARγ-ligand interactions of nitrogen heteroarotinoids
33. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships
34. Heteroarotinoids contain urea or thiourea linker
35. Ovarian and extraovarian mucinous tumors with solid mural nodules
36. Heterogeneity of mucin gene expression in normal and neoplastic tissues
37. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
38. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
39. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours
40. Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreaticobiliary epithelial cells
41. N-Acetyl-beta-D-glucosaminyltransferases related to the synthesis of mucin-type glycoproteins in human ovarian tissue
42. Mucin gene expression in ovarian cancers
43. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours
44. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells
45. Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids
46. Restoration of the mucous phenotype by retinoic acid in retinoid-deficient human bronchial cell cultures: Changes in mucin gene expression
47. Making the most of mucin: A novel target for tumor immunotherapy
48. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer gylcan chains in tumor cells
49. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components
50. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1
51. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer
52. Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition
53. All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1